358 related articles for article (PubMed ID: 19396424)
41. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
[TBL] [Abstract][Full Text] [Related]
42. Real-world outcomes with different technology modalities in type 1 diabetes.
Beato-Víbora PI; Gallego-Gamero F; Ambrojo-López A
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1845-1850. PubMed ID: 33838993
[TBL] [Abstract][Full Text] [Related]
43. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol.
McAuley SA; de Bock MI; Sundararajan V; Lee MH; Paldus B; Ambler GR; Bach LA; Burt MG; Cameron FJ; Clarke PM; Cohen ND; Colman PG; Davis EA; Fairchild JM; Hendrieckx C; Holmes-Walker DJ; Horsburgh JC; Jenkins AJ; Kaye J; Keech AC; King BR; Kumareswaran K; MacIsaac RJ; McCallum RW; Nicholas JA; Sims C; Speight J; Stranks SN; Trawley S; Ward GM; Vogrin S; Jones TW; O'Neal DN
BMJ Open; 2018 Jun; 8(6):e020274. PubMed ID: 29886443
[TBL] [Abstract][Full Text] [Related]
44. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
[TBL] [Abstract][Full Text] [Related]
45. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol.
Fuchs J; Allen JM; Boughton CK; Wilinska ME; Thankamony A; de Beaufort C; Campbell F; Yong J; Froehlich-Reiterer E; Mader JK; Hofer SE; Kapellen TM; Rami-Merhar B; Tauschmann M; Hood K; Kimbell B; Lawton J; Roze S; Sibayan J; Cohen N; Hovorka R;
BMJ Open; 2021 Feb; 11(2):e042790. PubMed ID: 33579766
[TBL] [Abstract][Full Text] [Related]
46. Incremental value of continuous glucose monitoring when starting pump therapy in patients with poorly controlled type 1 diabetes: the RealTrend study.
Raccah D; Sulmont V; Reznik Y; Guerci B; Renard E; Hanaire H; Jeandidier N; Nicolino M
Diabetes Care; 2009 Dec; 32(12):2245-50. PubMed ID: 19767384
[TBL] [Abstract][Full Text] [Related]
47. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
[TBL] [Abstract][Full Text] [Related]
48. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
49. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial.
Beck RW; Riddlesworth T; Ruedy K; Ahmann A; Bergenstal R; Haller S; Kollman C; Kruger D; McGill JB; Polonsky W; Toschi E; Wolpert H; Price D;
JAMA; 2017 Jan; 317(4):371-378. PubMed ID: 28118453
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
[TBL] [Abstract][Full Text] [Related]
51. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
[TBL] [Abstract][Full Text] [Related]
52. Report of a 7 year case-control study of continuous intraperitoneal insulin infusion and subcutaneous insulin therapy among patients with poorly controlled type 1 diabetes mellitus: favourable effects on hypoglycaemic episodes.
van Dijk PR; Logtenberg SJ; Groenier KH; Gans RO; Bilo HJ; Kleefstra N
Diabetes Res Clin Pract; 2014 Nov; 106(2):256-63. PubMed ID: 25305134
[TBL] [Abstract][Full Text] [Related]
53. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.
Šoupal J; Petruželková L; Grunberger G; Hásková A; Flekač M; Matoulek M; Mikeš O; Pelcl T; Škrha J; Horová E; Škrha J; Parkin CG; Svačina Š; Prázný M
Diabetes Care; 2020 Jan; 43(1):37-43. PubMed ID: 31530663
[TBL] [Abstract][Full Text] [Related]
54. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study.
Hirsch IB; Abelseth J; Bode BW; Fischer JS; Kaufman FR; Mastrototaro J; Parkin CG; Wolpert HA; Buckingham BA
Diabetes Technol Ther; 2008 Oct; 10(5):377-83. PubMed ID: 18715214
[TBL] [Abstract][Full Text] [Related]
55. Use of sensor-integrated pump therapy to reduce hypoglycaemia in people with Type 1 diabetes: a real-world study in the UK.
Choudhary P; de Portu S; Arrieta A; Castañeda J; Campbell FM
Diabet Med; 2019 Sep; 36(9):1100-1108. PubMed ID: 31134668
[TBL] [Abstract][Full Text] [Related]
56. Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study.
Boughton CK; Hartnell S; Thabit H; Mubita WM; Draxlbauer K; Poettler T; Wilinska ME; Hood KK; Mader JK; Narendran P; Leelarathna L; Evans ML; Hovorka R
Lancet Healthy Longev; 2022 Mar; 3(3):e135-e142. PubMed ID: 35359882
[TBL] [Abstract][Full Text] [Related]
57. Hybrid closed-loop insulin delivery versus sensor-augmented pump therapy in children aged 6-12 years: a randomised, controlled, cross-over, non-inferiority trial.
Kariyawasam D; Morin C; Casteels K; Le Tallec C; Sfez A; Godot C; Huneker E; Garrec N; Benhamou PY; Polak M; Charpentier G; Franc S; Beltrand J
Lancet Digit Health; 2022 Mar; 4(3):e158-e168. PubMed ID: 35216750
[TBL] [Abstract][Full Text] [Related]
58. Sleep quality and glycaemic variability in a real-life setting in adults with type 1 diabetes.
Brandt R; Park M; Wroblewski K; Quinn L; Tasali E; Cinar A
Diabetologia; 2021 Oct; 64(10):2159-2169. PubMed ID: 34136937
[TBL] [Abstract][Full Text] [Related]
59. Timing of CGM initiation in pediatric diabetes: The CGM TIME Trial.
Lawson ML; Verbeeten KC; Courtney JM; Bradley BJ; McAssey K; Clarson C; Kirsch S; Curtis JR; Mahmud FH; Richardson C; Cooper T; Chan J; Tang K
Pediatr Diabetes; 2021 Mar; 22(2):279-287. PubMed ID: 33098212
[TBL] [Abstract][Full Text] [Related]
60. Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET.
Cardona-Hernandez R; Schwandt A; Alkandari H; Bratke H; Chobot A; Coles N; Corathers S; Goksen D; Goss P; Imane Z; Nagl K; O'Riordan SMP; Jefferies C;
Diabetes Care; 2021 May; 44(5):1176-1184. PubMed ID: 33653821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
